Investigational drug · Phase 3
LB-102
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Schizophrenia, Bipolar I Disorder.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
6
Any phase or sponsor naming "LB-102"
First trial start
2023
Nov 29, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LB-102", any sponsor or status.
Conditions studied
As listed on its trial records.
- Schizophrenia
- Bipolar I Disorder
Approved drugs for the same conditions: Schizophrenia · Bipolar disorder · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "LB-102" as an intervention, largest first.
- 52-week Open Label Safety-Tolerability StudyPivotal-lookingRecruiting
LB Pharmaceuticals Inc.Industry
NCT07369154 · 900 participants (planned) · Start Apr 23, 2026 · Primary completion Dec 2028
Drug: LB-102 · For: Schizophrenia
Sites: Chandler, Arizona; Bentonville, Arkansas; Little Rock, Arkansas · 23 sites in all
- Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute SchizophreniaPivotal-lookingRecruiting
LB Pharmaceuticals Inc.Industry
NCT07363577 · 456 participants (planned) · Start Mar 25, 2026 · Primary completion Jun 2027
Drug: LB-102 (50 mg tablet); LB-102 (100 mg tablet) · For: Schizophrenia
Sites: Bentonville, Arkansas; Little Rock, Arkansas; Culver City, California · 13 sites in all
- Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute SchizophreniaPivotal-lookingCompleted
LB Pharmaceuticals Inc.Industry
NCT06179108 · 359 participants · Start Nov 29, 2023 · Primary completion Dec 4, 2024
Drug: LB-102 · For: Schizophrenia
Sites: Bentonville, Arkansas; Little Rock, Arkansas; Rogers, Arkansas · 25 sites in all
- Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.Pivotal-lookingRecruiting
LB Pharmaceuticals Inc.Industry
NCT07494305 · 320 participants (planned) · Start Jan 23, 2026 · Primary completion Feb 2028
Drug: LB-102 · For: Bipolar I Disorder
Sites: Bentonville, Arkansas; Little Rock, Arkansas; Bellflower, California · 26 sites in all
LB Pharmaceuticals Inc.Industry
NCT04187560 · 64 participants · Start Jan 22, 2020 · Primary completion Jul 1, 2020
Drug: LB-102 · For: Schizophrenia
Sites: Cincinnati, Ohio
- Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy VolunteersCompleted
LB Pharmaceuticals Inc.Industry
NCT04588129 · 16 participants · Start Jan 5, 2021 · Primary completion Sep 17, 2021
Drug: LB-102 · For: Schizophrenia
Sites: St Louis, Missouri
Newest research
PubMed records naming it or its code names, newest first.
- Are we moving forward from amisulpride? LB-102 (N-methyl amisulpride) in acute schizophrenia.
Doggrell SA · Expert Opin Investig Drugs 2026
- Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults With Acute Schizophrenia: A Randomized Clinical Trial.
Eramo A, Correll CU, Walling DP, et al. · JAMA Psychiatry 2026
- Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape.
Govil P, Kantrowitz JT · CNS Drugs 2025
- PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement.
Wong DF, Chand GB, Caito N, et al. · Neuropsychopharmacology 2024
- A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia.
Wu J, Kwan AT, Rhee TG, et al. · Expert Rev Clin Pharmacol 2023
- A randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB-102, a selective dopamine D2/3/5-HT7 inhibitor.
Biernat L, Grattan VT, Hixon MS, et al. · Psychopharmacology (Berl) 2022
Also in development for Schizophrenia
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- SEP-363856UlotarontPhase 37 trials
Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder
- NBI-1117568Phase 35 trials
Neurocrine Biosciences · Schizophrenia, Bipolar I Disorder, Mania
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- OLZSAM, ALKS 3831Phase 32 trials
Alkermes, Inc. · Bipolar I Disorder, Schizophrenia
- B2227Phase 31 trial
Bostal Drug Delivery Co., Ltd · Schizophrenia
- ML-007C-MAPhase 24 trials
MapLight Therapeutics · Psychosis Associated With Alzheimer's Disease, Schizophrenia
- ALTO-101Phase 21 trial
Alto Neuroscience · Schizophrenia, Cognitive Impairment
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.